Tag: Biosimilar

The average retail price for Fulphila is around $2,776, but cash prices with coupons can be as low as $2,046 for a 6 mg/0.6 mL syringe [1.2.8, 1.2.5]. This article details the various factors that answer the question: **How much does Fulphila cost in the US?**

While many patients ask, 'Is there a generic version of Eylea?', the correct term for its alternatives is 'biosimilar,' because Eylea is a complex biologic drug made from living cells. As of late 2024 and early 2025, the U.S. Food and Drug Administration (FDA) has approved multiple aflibercept biosimilars, though their market availability has been impacted by patent litigation.

The biologic drug Rituxan® was first approved by the FDA in 1997, and its generic name is rituximab. This monoclonal antibody has become a cornerstone therapy for various cancers and autoimmune conditions, with several biosimilar versions now available to offer patients more affordable options.

As of 2023, there are three FDA-approved biosimilars for Rituxan (rituximab) available in the United States, offering alternatives for patients and healthcare providers [1.5.3]. If you're asking, 'What is a substitute for RITUXAN?', it's important to understand these biosimilars and other therapeutic options.

In the United States, approximately 1.5 million people are living with rheumatoid arthritis (RA), many of whom rely on biologic medications [1.3.1]. For those prescribed Kevzara, a key question is: Is there a generic for Kevzara to help manage costs?

The U.S. Food and Drug Administration (FDA) first approved Truxima (rituximab-abbs) in 2018 as a biosimilar to Rituxan [1.3.1]. This raises a critical question for patients and providers: Is Truxima as good as Rituxan? This article examines the evidence.

Overproduction of the inflammatory protein TNF-alpha drives several autoimmune diseases, including rheumatoid arthritis and inflammatory bowel diseases. **What is the mechanism of action of Renflexis?** This biological medicine works by targeting and neutralizing this key inflammatory protein to reduce inflammation.

In clinical trials, many people taking Cosentyx for plaque psoriasis have shown significant improvement. The generic name for Cosentyx is **secukinumab**, and it is important to understand what this means for patients with autoimmune conditions.

Most patients using adalimumab, the active ingredient in Hulio, begin to feel some symptom relief within 2 to 12 weeks of starting treatment. As a biologic medication, Hulio is not a painkiller and works by addressing the underlying cause of inflammation, meaning its full therapeutic effects develop gradually over several months. The precise timeline for experiencing the benefits of Hulio depends on the specific condition being treated, disease severity, and other individual patient factors.

Did you know that in the U.S., biosimilars like Hulio entered the market after Humira's patents expired, offering more affordable treatment options? The core question, **Is Hulio the same as Humira?**, has a nuanced answer concerning their biological nature, safety, and effectiveness.